Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (F508del Homozygous)
NCT04105972Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Oct 2019; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04105972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105972.